NCT02545335 is a clinical trial in Chronic Hepatitis C, sponsored by Medical University of Graz.

Who is sponsoring NCT02545335?

NCT02545335 is sponsored by Medical University of Graz.

What condition does NCT02545335 study?

NCT02545335 studies Chronic Hepatitis C.

Is NCT02545335 still recruiting?

NCT02545335 is currently completed. Last updated 12 January 2023.

Last reviewed 2023-01-12 · How we verify

NCT02545335

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C

Completed Last updated 12 January 2023

What this trial tests

trial in Chronic Hepatitis C in 174 participants. Completed in 31 December 2020.

Timeline

1 November 2014

Primary endpoint
31 December 2020

31 December 2020

Quick facts

Lead sponsor	Medical University of Graz
Status	Completed
Study type	OBSERVATIONAL
Enrollment	174
Start date	1 November 2014
Primary completion	31 December 2020
Estimated completion	31 December 2020
Sites	1 location across Austria

Conditions studied

Chronic Hepatitis C — all drugs for Chronic Hepatitis C →

Sponsor

Medical University of Graz

Who can join

Adults 18 to 99, any sex, with Chronic Hepatitis C. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to characterize neutrophil function in patients undergoing chronic hepatitis C triple therapy with protease inhibitors in comparison to dual therapy with peginterferon and ribavirin and with interferon free treatment regimen to thereby elucidate the possible mechanisms of protease-inhibitor associated infections.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Triple Therapy with First Generation Protease Inhibitors for Hepatitis C Markedly Impairs Function of Neutrophil Granulocytes.
Spindelboeck W, Horvath A, Tawdrous M, Schmerböck B, et al · · 2016 · cited 2× · PMID 26938078 · DOI 10.1371/journal.pone.0150299

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis C

Currently open trials in the same condition.

NCT06180590 — The Efficacy of Vosevi in Treating DAA-experienced Patients · recruiting
NCT03993925 — Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong · active not recruiting

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02545335 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 12 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02545335.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing